T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy

Title
T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy
Authors
류주희김한영강미경홍지혜정문교권성필송석영이주로강서경한진구자현임송현손희수최제민도준상김병수
Issue Date
2020-10
Publisher
Advanced materials
Citation
VOL 32, NO 39-2003377
Abstract
Cancer immunotherapies, including adoptive T cell transfer and immune checkpoint blockades, have recently shown considerable success in cancer treatment. Nevertheless, transferred T cells often become exhausted because of the immunosuppressive tumor microenvironment. Immune checkpoint blockades, in contrast, can reinvigorate the exhausted T cells; however, the therapeutic efficacy is modest in 70?80% of patients. To address some of the challenges faced by the current cancer treatments, here T­cell­membrane­coated nanoparticles (TCMNPs) are developed for cancer immunotherapy. Similar to cytotoxic T cells, TCMNPs can be targeted at tumors via T­cell­membrane­originated proteins and kill cancer cells by releasing anticancer molecules and inducing Fas­ligand­mediated apoptosis. Unlike cytotoxic T cells, TCMNPs are resistant to immunosuppressive molecules (e.g., transforming growth factor­β1 (TGF­β1)) and programmed death­ligand 1 (PD­L1) of cancer cells by scavenging TGF­β1 and PD­L1. Indeed, TCMNPs exhibit higher therapeutic efficacy than an immune checkpoint blockade in melanoma treatment. Furthermore, the anti­tumoral actions of TCMNPs are also demonstrated in the treatment of lung cancer in an antigen­nonspecific manner. Taken together, TCMNPs have a potential to improve the current cancer immunotherapy.
URI
http://pubs.kist.re.kr/handle/201004/72398
ISSN
0935-9648
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE